

Jifei Miao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9073395/publications.pdf>

Version: 2024-02-01

10
papers

186
citations

1307594

7
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

229
citing authors

#	ARTICLE	IF	CITATIONS
1	Paeonol attenuates inflammation by confining HMGB1 to the nucleus. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 2885-2899.	3.6	14
2	Protective effect of plastrum testudinis extract on dopaminergic neurons in a Parkinson's disease model through DNMT1 nuclear translocation and SNCA's methylation. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111832.	5.6	9
3	Rhein attenuates lipopolysaccharide-primed inflammation through NF- κ B inhibition in RAW264.7 cells: targeting the PPAR- δ signal pathway. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 357-365.	1.4	18
4	Paeonol promotes the phagocytic ability of macrophages through confining HMGB1 to the nucleus. <i>International Immunopharmacology</i> , 2020, 89, 107068.	3.8	12
5	Nuclear HMGB1 promotes the phagocytic ability of macrophages. <i>Experimental Cell Research</i> , 2020, 393, 112037.	2.6	11
6	Paeonol attenuates inflammation by targeting HMGB1 through upregulating miR-339-5p. <i>Scientific Reports</i> , 2019, 9, 19370.	3.3	23
7	Anti-Inflammatory Effects of Shenfu Injection against Acute Lung Injury through Inhibiting HMGB1-NF- κ B Pathway in a Rat Model of Endotoxin Shock. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-10.	1.2	18
8	Chrysophanol demonstrates anti-inflammatory properties in LPS-primed RAW 264.7 macrophages through activating PPAR- δ . <i>International Immunopharmacology</i> , 2018, 56, 90-97.	3.8	44
9	Paeonol Reduces the Nucleocytoplasmic Transportation of HMGB1 by Upregulating HDAC3 in LPS-Induced RAW264.7 Cells. <i>Inflammation</i> , 2018, 41, 1536-1545.	3.8	8
10	Paeonol attenuates acute lung injury by inhibiting HMGB1 in lipopolysaccharide-induced shock rats. <i>International Immunopharmacology</i> , 2018, 61, 169-177.	3.8	29